Ulisse Biomed S.p.A. (UBM.MI)
EUR 0.76
(-2.56%)
EUR 0.76
(-2.56%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 66.2 Thousand EUR | -52.17% |
| 2022 | 138.43 Thousand EUR | -49.96% |
| 2021 | 276.62 Thousand EUR | -35.52% |
| 2020 | 429 Thousand EUR | 3800.0% |
| 2019 | 11 Thousand EUR | 14373.68% |
| 2018 | 76.00 EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 185.42 Thousand EUR | 0.0% |
| 2024 Q1 | 185.42 Thousand EUR | 640.7% |
| 2023 FY | 66.2 Thousand EUR | -52.17% |
| 2023 Q3 | 25.03 Thousand EUR | 55.11% |
| 2023 Q4 | 25.03 Thousand EUR | 0.0% |
| 2023 Q2 | 16.13 Thousand EUR | 99.99% |
| 2023 Q1 | 8070.00 EUR | -89.21% |
| 2022 Q2 | 63.66 Thousand EUR | 100.0% |
| 2022 FY | 138.43 Thousand EUR | -49.96% |
| 2022 Q3 | 37.38 Thousand EUR | -41.28% |
| 2022 Q1 | 31.83 Thousand EUR | -75.66% |
| 2022 Q4 | 74.76 Thousand EUR | 100.0% |
| 2021 FY | 276.62 Thousand EUR | -35.52% |
| 2021 Q1 | 72.92 Thousand EUR | -82.94% |
| 2021 Q2 | 145.84 Thousand EUR | 100.0% |
| 2021 Q3 | 67.29 Thousand EUR | -53.86% |
| 2021 Q4 | 130.78 Thousand EUR | 94.34% |
| 2020 Q2 | 1188.00 EUR | -95.18% |
| 2020 FY | 429 Thousand EUR | 3800.0% |
| 2020 Q3 | 278.11 Thousand EUR | 23310.02% |
| 2020 Q1 | 24.63 Thousand EUR | 0.0% |
| 2020 Q4 | 427.42 Thousand EUR | 53.69% |
| 2019 FY | 11 Thousand EUR | 14373.68% |
| 2018 FY | 76.00 EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ARTERRA BIOSCIENCE | 3.33 Million EUR | 98.016% |
| Philogen S.p.A. | 23.13 Million EUR | 99.714% |